ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 146 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $922 | +491.0% | 99,161 | +531.2% | 0.01% | +400.0% |
| Q1 2024 | $156 | +97.5% | 15,709 | -35.5% | 0.00% | 0.0% |
| Q4 2023 | $79 | -70.8% | 24,356 | -14.3% | 0.00% | -50.0% |
| Q2 2023 | $271 | -3.2% | 28,414 | +11.5% | 0.00% | -33.3% |
| Q1 2023 | $280 | -99.9% | 25,482 | +125.6% | 0.00% | 0.0% |
| Q3 2022 | $216,000 | -25.8% | 11,296 | -17.2% | 0.00% | 0.0% |
| Q2 2022 | $291,000 | +70.2% | 13,646 | +65.4% | 0.00% | +200.0% |
| Q4 2021 | $171,000 | -63.8% | 8,251 | -58.3% | 0.00% | -50.0% |
| Q3 2021 | $473,000 | -30.2% | 19,783 | -20.4% | 0.00% | -33.3% |
| Q2 2021 | $678,000 | +2.9% | 24,848 | +9.1% | 0.00% | 0.0% |
| Q1 2021 | $659,000 | +167.9% | 22,782 | +179.8% | 0.00% | +50.0% |
| Q2 2020 | $246,000 | +123.6% | 8,142 | +120.9% | 0.00% | +100.0% |
| Q1 2020 | $110,000 | – | 3,686 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $128,526,634 | 7.99% |
| Saturn V Capital Management LP | 487,179 | $8,787,113 | 7.29% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $44,400 | 4.96% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $8,421,807 | 3.66% |
| Logos Global Management LP | 1,400,000 | $20,720,000 | 2.43% |
| Rubric Capital Management LP | 2,742,519 | $40,589,281 | 1.77% |
| 1492 Capital Management LLC | 174,546 | $2,583,281 | 1.67% |
| AlphaCentric Advisors LLC | 78,500 | $1,161,800 | 1.15% |
| MPM BioImpact LLC | 262,069 | $3,878,621 | 1.01% |
| Orbimed Advisors | 2,460,108 | $36,409,598 | 0.70% |